The Institute of Grocery Distribution (IGD) has announced a new insight programme, IGD Futures: GLP‑1, to help food industry businesses “understand, navigate and capitalise on the impacts of weight loss medication use,” it said.
Its latest research shows weight loss medication (GLP-1s) usage is rising fast, with uptake among UK adults growing from 3.1% in June 2025 to 4.2% in October - more than the number following a vegan diet.
The IGD also reveals 35% of GLP-1 users eating out less often, 69% eating fewer snacks and 48% eating fewer meals overall, which will naturally affect the food industry and shopper behaviour.
Earlier this month, the Co-op announced plans to launch a weight loss drug-friendly meals range.
The new programme is designed to provide a total view of current and future changes in consumer and shopper behaviours, household dynamics and category demand. It also brings together insights on wider GLP-1 impacts, such as global trends and the evolving science and regulations.
Tom Wakeman, insight director at the IGD, said: “Consistently, the industry tells us they need to understand who is changing, how they are changing and where the opportunities are.
“We’ve structured this programme to help businesses turn behaviour change into commercial advantage. Our approach reveals what’s shifting, why, and what actions will unlock value. Powered by deep insight, it projects the scale of impact so businesses can stay ahead.”
You can now secure your tickets to the Convenience Awards 2026!
Join us on 11 March in Liverpool to celebrate the entire convenience community.
See this year’s finalists and book your seat here.
No comments yet